Ocumension Therapeutics - Laporan Laba Rugi (TTM)

Ocumension Therapeutics
HK ˙ SEHK ˙ KYG674111011
HK$ 10.50 ↑1.24 (13.39%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Ocumension Therapeutics menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 8 13 23 32 44 56 73 90 124 159 184 208 227 246 278 310 364 417 481 544
Change (%) 71.89 71.97 41.85 37.87 27.47 30.04 23.10 38.43 27.76 15.46 13.39 9.19 8.42 12.97 11.48 17.24 14.71 15.15 13.15
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1 2 4 7 13 19 27 34 45 56 66 77 89 102 116 129 161 192 252 312
Change (%) 96.36 147.74 59.63 90.88 47.61 39.34 28.23 31.63 24.03 18.52 15.62 16.41 14.10 13.45 11.85 24.26 19.52 31.20 23.78
% of Revenue 11.52 13.16 18.96 21.34 29.55 34.22 36.66 38.19 36.32 35.26 36.19 36.90 39.34 41.40 41.58 41.71 44.21 46.07 52.49 57.42
Gross Operating Profit 7 11 18 25 31 37 46 56 79 103 117 131 138 144 163 181 203 225 228 232
Change (%) 68.70 60.49 37.69 23.49 19.02 25.20 20.13 42.63 29.89 13.80 12.13 4.97 4.73 12.64 11.22 12.22 10.89 1.43 1.41
% of Revenue 88.48 86.84 81.04 78.66 70.45 65.78 63.34 61.81 63.68 64.74 63.81 63.10 60.66 58.60 58.42 58.29 55.79 53.93 47.51 42.58
SG&A 242 284 252 220 237 254 279 305 340 374 405 435 429 423 416 409 414 418 418 418
Change (%) 17.37 -11.27 -12.70 7.78 7.22 10.09 9.16 11.39 10.22 8.03 7.43 -1.36 -1.38 -1.57 -1.60 0.99 0.98 0.03 0.03
% of Revenue 3,170.65 2,165.09 1,117.06 687.44 537.41 452.05 382.69 339.36 273.07 235.58 220.41 208.82 188.64 171.59 149.50 131.96 113.66 100.06 86.93 76.85
R&D 150 180 200 220 194 169 172 175 180 184 172 159 141 124 117 109 112 114 104 94
Change (%) 19.56 11.18 10.05 -11.52 -13.02 1.83 1.80 2.58 2.52 -6.88 -7.38 -11.07 -12.45 -5.81 -6.17 2.08 2.04 -8.65 -9.47
% of Revenue 1,971.13 1,371.03 886.34 687.65 441.28 301.10 235.79 194.99 144.50 115.95 93.51 76.38 62.21 50.24 41.88 35.25 30.69 27.30 21.66 17.33
OpEx 393 465 455 446 444 442 478 515 565 615 643 670 659 649 648 648 686 724 774 824
Change (%) 18.38 -2.01 -2.05 -0.45 -0.46 8.20 7.58 9.74 8.87 4.52 4.32 -1.63 -1.65 -0.02 -0.02 5.82 5.50 6.95 6.49
% of Revenue 5,153.30 3,549.28 2,022.36 1,396.43 1,008.24 787.36 655.14 572.54 453.88 386.78 350.11 322.10 290.19 263.23 232.96 208.92 188.57 173.43 161.08 151.60
Operating Income -385 -452 -433 -414 -400 -386 -405 -425 -440 -456 -459 -462 -432 -402 -370 -338 -322 -306 -293 -281
Change (%) 17.33 -4.16 -4.34 -3.41 -3.53 5.03 4.78 3.67 3.54 0.70 0.69 -6.50 -6.95 -7.98 -8.67 -4.67 -4.89 -4.22 -4.41
% of Revenue -5,053.30 -3,449.28 -1,922.36 -1,296.43 -908.24 -687.36 -555.14 -472.54 -353.88 -286.78 -250.11 -222.10 -190.19 -163.23 -132.96 -108.92 -88.57 -73.43 -61.08 -51.60
Interest Expense -0 -0 -0 -0 -0 -1 -1 -1 -1 -2 -2 -1 -1 -1 -2 -3 -2 -2 -2 -1
Change (%) 0.85 281.36 73.78 22.51 18.37 55.20 35.57 25.15 20.09 -9.54 -10.54 -4.34 -4.54 44.83 30.95 -6.96 -7.49 -23.19 -30.18
% of Revenue -0.77 -0.45 -1.00 -1.22 -1.09 -1.01 -1.21 -1.33 -1.20 -1.13 -0.88 -0.70 -0.61 -0.54 -0.69 -0.81 -0.64 -0.52 -0.35 -0.21
Net Income -2,540 -2,265 -1,429 -593 -426 -260 -322 -383 -393 -403 -411 -418 -399 -380 -351 -323 -296 -268 -259 -249
Change (%) -10.85 -36.92 -58.52 -28.07 -39.02 23.67 19.14 2.56 2.49 1.95 1.92 -4.61 -4.83 -7.51 -8.12 -8.44 -9.21 -3.55 -3.68
% of Revenue -33,344.14 -17,294.33 -6,344.10 -1,855.28 -967.95 -463.06 -440.37 -426.19 -315.75 -253.30 -223.67 -201.03 -175.62 -154.15 -126.20 -104.01 -81.23 -64.29 -53.85 -45.84

Source: Capital IQ

Other Listings
DE:5DG € 1.12
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista